Please login to the form below

Not currently logged in
Email:
Password:

AZ settles Seroquel patent case

AstraZeneca has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR in the US

AstraZeneca (AZ) has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR (quetiapine humarate) in the US.

AZ filed litigation against Accord following the company's submission to the US Food and Drug Administration (FDA) of an abbreviated new drug application for a generic version of the depression treatment.

As part of the agreement, AZ has granted Accord a licence to enter the US market with its generic Seroquel XR on November 1, 2016, or earlier, depending upon certain circumstances.

The drug is protected by patents and other exclusivity rights that range from March 2012 to November 2017.

Remaining Seroquel XR patent infringement litigations are ongoing.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics